ImmunGene Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 6

  • Investments
  • 1

ImmunGene General Information

Description

Developer of therapeutic drugs designed to treat cancer, autoimmune creating disorders, and other diseases. The company's therapeutic drugs are the next generation of monoclonal antibody-based therapeutics, thereby enabling healthcare institutions to avail drugs that primarily focus on safe and effective treatments for cancer and serious diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • 480 Constitution Avenue
  • Camarillo, CA 93012
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 480 Constitution Avenue
  • Camarillo, CA 93012
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunGene Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ImmunGene‘s full profile, request access.

Request a free trial

ImmunGene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic drugs designed to treat cancer, autoimmune creating disorders, and other diseases. The company'
Drug Discovery
Camarillo, CA

Beijing, China
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmunGene Competitors (105)

One of ImmunGene’s 105 competitors is Mabworks Biotech, a Venture Capital-Backed company based in Beijing, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mabworks Biotech Venture Capital-Backed Beijing, China
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Alzheon Venture Capital-Backed Framingham, MA
Cognition Therapeutics Formerly VC-backed New York, NY
You’re viewing 5 of 105 competitors. Get the full list »

ImmunGene Patents

ImmunGene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2017180764-A1 Focused interferon immunotherapy Inactive 12-Apr-2016
WO-2017091611-A1 Enhanced cancer immunotherapy using antibody-interferon fusion molecules Inactive 23-Nov-2015
WO-2017087843-A1 Methods of treating proliferative diseases using engineered antibody-interferon fusion molecules Inactive 20-Nov-2015
WO-2016201350-A1 Combination therapy for treatment of cancer Inactive 12-Jun-2015
WO-2016201337-A1 Engineered antibody-interferon fusion molecules for the treatment of glucose-regulated protein 94 (grp94) expressing cancers Inactive 12-Jun-2015 C07K14/555
To view ImmunGene’s complete patent history, request access »

ImmunGene Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ImmunGene‘s full profile, request access.

Request a free trial

ImmunGene Investments (1)

ImmunGene’s most recent deal was a Joint Venture with Valor Biotherapeutics. The deal was made on 13-Nov-2012.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Valor Biotherapeutics 13-Nov-2012 Joint Venture Biotechnology
To view ImmunGene’s complete investments history, request access »

ImmunGene Exits (1)

ImmunGene’s most recent exit was on 13-Nov-2012 from Valor Biotherapeutics. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Valor Biotherapeutics 13-Nov-2012 Completed
  • 2 buyers
To view ImmunGene’s complete exits history, request access »

ImmunGene FAQs

  • When was ImmunGene founded?

    ImmunGene was founded in 2007.

  • Where is ImmunGene headquartered?

    ImmunGene is headquartered in Camarillo, CA.

  • What industry is ImmunGene in?

    ImmunGene’s primary industry is Drug Discovery.

  • Is ImmunGene a private or public company?

    ImmunGene is a Private company.

  • What is ImmunGene’s current revenue?

    The current revenue for ImmunGene is .

  • How much funding has ImmunGene raised over time?

    ImmunGene has raised $9M.

  • Who are ImmunGene’s investors?

    Ally Bridge Group, Ennovation Ventures, and WP Global Partners have invested in ImmunGene.

  • Who are ImmunGene’s competitors?

    Mabworks Biotech, Inovio Pharmaceuticals, CytomX Therapeutics, Alzheon, and Cognition Therapeutics are some of the 105 competitors of ImmunGene.

  • When was ImmunGene acquired?

    ImmunGene was acquired on 01-Apr-2019.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process